Introduction/Objective Patients who have had symptoms for more than 12h before receiving treatment are considered to be myocardial infarction late presenters. The literature contains scarce and often controversial data about treating such patients. The objective of the paper is to present treatment outcome in patients with acute ST-elevation myocardial infarction (STEMI), whose therapy was initiated more than 12h and less than 48 hours after the onset of symptoms. Methods the research included 130 patients who had suffered from acute STEMI in 2017, all of whom presented more than 12h and less than 48h after the onset of symptoms. A primary percutaneous coronary intervention (PPCI) was used to treat 109 patients, while 21 patients were treated conservatively. An analysis was performed correlating treatment results, intrahospital mortality, one-year survival rate depending on the type of treatment, risk factors and comorbidity. Results A statistically significant difference (x 2 =7,119; p=0,017) has been verified when comparing the mortality of STEMI patients treated with PPCI(8.3%) and those treated conservatively (28.6%). A statistically significant difference (t=9,385; p=0,005) has been verified when it came to treating STEMI patients that were also suffering from diabetes. In the group treated with PPCI, 77.8% of the patients that had died had diabetes. No comorbidity showed a statistically significant difference in distribution depending on the type of treatment and treatment results. Conclusion When deciding on the type of treatment these patients shall receive, the following should be taken into consideration: clinical presentation, hemodynamic status and presence of life-threatening arrhythmias. There is still no clear guideline for treating such patients.